Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

CP-724,714 in Treating Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00055926
Recruitment Status : Completed
First Posted : March 7, 2003
Last Update Posted : August 3, 2020
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:

RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have metastatic HER2-overexpressing breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: CP-724,714 Phase 1

Detailed Description:


  • Determine the safety and tolerability of CP-724,714 in patients with metastatic HER2-overexpressing breast cancer.
  • Determine the maximum tolerated dose of this drug in these patients.
  • Determine, preliminarily, any antitumor activity of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the relationship of drug-related adverse events to pharmacokinetic exposure parameters in these patients.
  • Determine the relationship of changes in serum HER2 extracellular domain and HER2 receptor tyrosine kinase phosphorylation to pharmacokinetic exposure parameters and clinical outcome in patients treated with this drug.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive oral CP-724,714 on days 1 and 3-21 during course 1 and then daily during subsequent courses. Courses repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of CP-724,714 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed for at least 30 days.

PROJECTED ACCRUAL: A total of 3-20 patients will be accrued for this study within 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
Study Start Date : January 2003
Actual Primary Completion Date : December 2004
Actual Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed HER2-overexpressing breast cancer
  • Prior or newly documented HER2 amplification by fluorescence in situ hybridization (FISH)
  • Progressive metastatic disease
  • Must have received at least one prior chemotherapy regimen for metastatic breast cancer
  • At least 1 measurable or evaluable lesion
  • At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic evaluation
  • 18 and over
  • Male or female
  • ECOG 0-1
  • Life expectancy, More than 3 months
  • Hematopoietic

    • Absolute neutrophil count at least 1,500/mm^3*
    • Platelet count at least 100,000/mm^3* NOTE: *Without hematopoietic growth factors or transfusions
  • Hepatic

    • Bilirubin no greater than 1.5 mg/dL
    • AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
  • Renal

    • Creatinine no greater than 1.5 times ULN OR
    • Creatinine clearance at least 60 mL/min
  • Cardiovascular

    • 12-lead ECG with normal tracing
  • history of cardiovascular disease (i.e., ischemic heart disease, arrhythmia, or congestive heart failure) unless asymptomatic for the past year with no requirement for antiarrhythmics or a clinically significant medical management change
  • Gastrointestinal

    • Able to take oral medication* Negative pregnancy test
    • Fertile patients must use effective contraception
  • At least 4 weeks since prior trastuzumab (Herceptin)
  • At least 4 weeks since other prior biologic therapy or immunotherapy
  • At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)
  • At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy
  • No cumulative doses of more than 300 mg/m^2
  • At least 2 weeks since prior hormonal therapy for the primary disease
  • Concurrent hormone replacement therapy or luteinizing hormone-releasing hormone agonists allowed
  • At least 4 weeks since prior radiotherapy
  • At least 3 weeks since prior major surgery (2 weeks for minor surgery)
  • Recovered from prior therapy
  • At least 4 weeks since prior investigational treatment
  • Coumarin or heparin derivatives allowed for the prevention of deep vein thrombosis or port patency

Exclusion Criteria:

  • known or clinically suspected brain metastases or leptomeningeal disease
  • symptomatic edema or third-space fluid (e.g., ascites or pleural effusions)
  • known hepatitis B or C infection
  • significant ECG changes that require medical intervention
  • QTc interval less than 460 msec
  • No history of torsade or other symptomatic QTc abnormality
  • LVEF greater than 50% by MUGA
  • gastrointestinal abnormality that would require medications (including all antacids)
  • persistent symptoms of an esophageal or digestive disorder
  • pregnant or nursing
  • known HIV infection
  • active infection
  • concurrent uncontrolled systemic disorders or laboratory abnormalities that would preclude study drug safety evaluation
  • mental disorder that would preclude study compliance or ability to give informed consent
  • No more than 2 prior trastuzumab-based regimens for advanced disease
  • concurrent immunotherapy
  • more than 1 prior anthracycline- or anthracenedione-containing regimen (except with approval of the sponsor)
  • prior high-dose chemotherapy with hematopoietic stem cell transplantation
  • concurrent anticancer chemotherapy
  • No concurrent anticancer hormonal therapy, including tamoxifen
  • prior radiotherapy to the only disease site that would be assessed for response
  • concurrent radiotherapy
  • prior partial or complete gastrectomy
  • concurrent antiarrhythmics
  • concurrent antacids
  • concurrent anticoagulant at therapeutic doses
  • other concurrent experimental anticancer medications for breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00055926

Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Layout table for investigator information
Principal Investigator: Carolyn Britten, MD Jonsson Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00055926    
Other Study ID Numbers: CDR0000271533
First Posted: March 7, 2003    Key Record Dates
Last Update Posted: August 3, 2020
Last Verified: August 2012
Keywords provided by Jonsson Comprehensive Cancer Center:
recurrent breast cancer
stage IV breast cancer
male breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases